Although large, single-fraction, stereotactic radiosurgery (SRS) series of intracranial meningiomas exist, there is limited information on hypofractionated stereotactic radiotherapy (SRT). The purpose of this study is to report long-term results of an institutional standard of 25Gy/5 fractions (fx), hypofractionated frameless robotic radiosurgery for intracranial meningiomas. An IRB-approved retrospective analysis at a single institution was conducted. All intracranial meningiomas treated with frameless robotic radiosurgery hypofractionated (2-5fx) SRT at a single institution 2005-2015 were identified from an ongoing database. Although most intracranial meningiomas were treated with stereotactic radiosurgery frameless robotic radiosurgery was occasionally selected for proximity to optic nerves, chiasm, venous sinuses, or size. Data was gathered from available chart documentation, diagnostic reports, and electronic images. Follow-up was the date of last magnetic resonance imaging (MR) or death. Progression was scored according to The Radiographic Assessment for Neuro-Oncology (RANO) criteria. Actuarial local progression free survival (PFS), overall survival (OS) and local control (LC) were determined from time of CK SRT completion using the Kaplan-Meier method. Twenty-eight meningiomas in 25 patients were identified: 23 grade 1 and 5 grade 2 meningiomas, of which 74% and 100% were pathologically confirmed, respectively. Twenty-six percent of grade 1 tumors were previously untreated, 57% were recurrent and 17% were treated adjuvantly; 80% of grade 2 tumors were recurrent. Treatment dose was 25Gy/5 fx for all patients, given over a median of 7 days (range 5-15) at a median prescription isodose of 57% (50-81). The median planning target volume was 8.5 mL (3.4 - 32.4), defined as the contrast enhancing tumor (or surgical cavity); a planning margin of 0-2 mm was occasionally added at the discretion of the treating physician. Median follow-up was 81 months (range 2-133) for grade 1 and 102 months (20-118) for grade 2 meningiomas. Two grade 1 patients were lost to follow-up prior to 5 years of MR imaging at 2 and 28 months. Another patient died prior to any follow-up imaging. Grade I actuarial LC at 5 and 10 years was 94% and 79%, respectively. Corresponding local PFS and OS were 79% and 67% and 79% and 79%, respectively. Two of three grade 1 local failures were marginal. Two of five grade 2 meningiomas failed locally at 30 and 46 months. No patient experienced clinically significant perilesional edema or vision changes secondary to radiation. Hypofractionated 25Gy/5 fx SRT offers excellent local control for grade 1 meningiomas. While proportionately more grade 2 meningiomas failed locally, the small numbers make meaningful conclusions difficult. This study supports the use of CK SRT 25Gy/5 fx for selected grade 1 meningiomas near optic structures, venous sinuses or of larger size.